Phase 2 N=65 Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia (ALL)
Primary: Complete Remission Plus Complete Remission Without Full Platelet Recovery (CR + CRi) — 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=68 S9912 Combination Chemo in Stage III Ovarian Cancer,
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Progression-free Survival — 25 months
Phase 2 N=62 AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.
Advanced Breast Cancer
Primary: Progression Free Survival — 223; 112 Days
Phase 2 N=49 A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Carcinoma, Renal Cell
Primary: Objective Tumor Response — 31.3 Percentage of participants
Phase 2 N=342 Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
Lung Cancer
Primary: Number of Patients Maintaining Stable Disease or Objective Response 2 Months After Randomization — 0; 0; 27; 7 participants — p=0.005
Phase 2 N=20 Atomoxetine and Huntington's Disease
Huntington Disease · Chorea
Primary: Conners' Adult Attention Rating Scale (CAARS) — -2.88; -2.24 units on a scale — p=0.63
Phase 2 N=120 A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
Non-Small-Cell Lung Cancer
Primary: Phase 1 - Maximum Tolerated Dose (MTD) of Carboplatin — NA milligram/milliliter*minute (mg/mL*min)
Phase 2 N=75 Topical IL-1-Ra for Treatment of Posterior Blepharitis
Posterior Blepharitis
Primary: Meibomian Gland Secretion Quality — 1.7; 1.7; 1.8 Units on a scale
Phase 2 N=53 Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Amphetamine-Related Disorders · HIV · HIV Infections
Primary: Self-reported Methamphetamine Use in Previous 30 Days. — 1.6 days
Phase 2 N=73 Fibrin Sealant Vascular Surgery Study
Adjunct to Hemostasis in Vascular Surgery (Synthetic Vascular Grafts)
Primary: Percentage of Participants Achieving Hemostasis at 4 Minutes After Treatment Application at the Study Suture Line. — 46.2; 62.5; 34.8; 30.8 percentage of participants
Phase 2 N=24 A Clinical Pharmacological Study of Rabeprazole Sodium in Japanese Healthy Adult Male Volunteers (Study E3810)
Healthy
Primary: Percentage Duration With An Intragastric pH >= 4 During The Entire 24 Hours Of Day 5 Administration — 45.63; 57.81; 61.36; 71.52 Percentage of Time in a 24 Hour Period
Phase 2 N=530 Evaluate Efficacy, Safety and Tolerability of AZD1656 as Add-on Treatment to Metformin in Type 2 Diabetes Mellitus (TD2M) Patients
Type II Diabetes Mellitus
Primary: HbA1c: Change From Baseline to 4 Month — -1.25; -1.26; -0.67; -0.61 Percentage
Phase 2 N=392 Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
Primary: Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. — 0; 32; 15…
Phase 2 N=20 Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
Type II Diabetes
Primary: Systolic Blood Pressure, Change From Baseline to End of Treatment — 0.4; 5.0 mmHg
Phase 2 N=257 Safety and Tolerability of QVA149 (Indacaterol/Glycopyrrolate) Compared to Placebo and to Indacaterol in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Change From Baseline in Mean 24 Hour Heart Rate at Day 14 — -0.113; 0.787; -0.230; 0.240 beats per minute